Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States

Rhea-AI Summary

Bionomics (Nasdaq: BNOX) is urging shareholders to vote on their proposed re-domiciliation from Australia to the United States. The company's Board of Directors and an independent expert have unanimously determined that the re-domiciliation through the Scheme Implementation Agreement is in shareholders' best interests.

The voting deadlines are December 3, 2024, 10:00 am New York time for American Depositary Shares holders and December 10, 2024, 8:30 am Sydney time for ordinary shares holders. The Scheme Meeting will be held virtually on December 12, 2024, at 8:30 am Sydney time (December 11, 2024, 4:30 pm New York time).

ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, is reminding Shareholders to cast their vote in favor of the Scheme Implementation Agreement to re-domicile Bionomics from Australia to the U.S.

“The re-domiciliation of Bionomics through the Scheme is key for our ability to execute our strategic vision and set the Company for success. I’d like to highlight that voting in favor of the Scheme was determined to be in the best interests of Bionomics Shareholders unanimously by the Board of Directors and an independent expert,” said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics. “I would like to thank each of the Shareholders that have already cast their vote and encourage those who haven’t yet to do so well in advance of the Proxy cut-off date of 10:00 am New York time on December 3, 2024 for holders of American Depositary Shares and 8:30 am Sydney time on December 10, 2024 for holders of ordinary shares.”

Bionomics Shareholders should carefully read the Scheme Booklet in its entirety before deciding on how to vote on the Scheme. The Scheme Meeting will be held at 8:30 am Sydney time on Thursday 12 December 2024 / 4:30 pm New York time on Wednesday 11 December 2024 via Bionomics’ online meeting platform at https://meetnow.global/MCKR7AV.

FOR FURTHER INFORMATION PLEASE CONTACT:

General Rajeev Chandra Company Secretary CoSec@bionomics.com.au	Investor Relations Kevin Gardner kgardner@lifesciadvisors.com	Investor Relations Chris Calabrese ccalabrese@lifesciadvisors.com

About Bionomics Limited
Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other CNS conditions. Bionomics’ pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need. www.bionomics.com.au

Forward-Looking Statements
Bionomics cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the closing of each tranche of the Company’s private placement financing, the achievement of certain milestones for the various tranches, the timely funding to the Company by each investor in the private placement, the timing, size and expectation of the closing of the private placement; and expectations regarding market conditions, the satisfaction of customary closing conditions related to the private placement and the anticipated use of proceeds therefrom; and the Company’s expectation that its current cash, cash equivalents, and marketable securities will fund our operations into the third quarter of 2025. The inclusion of forward-looking statements should not be regarded as a representation by Bionomics that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the Securities and Exchange Commission (SEC), including, but not limited to, the Company’s Annual Report on Form 20-F filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Bionomics undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks, uncertainties and other factors is included in Bionomics’ filings with the SEC, copies of which are available from the SEC’s website (www.sec.gov) and on Bionomics’ website (www.bionomics.com.au) under the heading “Investor Center.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Bionomics expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

FAQ

When is the deadline for Bionomics (BNOX) shareholders to vote on the re-domiciliation scheme?

The voting deadline is December 3, 2024, 10:00 am New York time for American Depositary Shares holders and December 10, 2024, 8:30 am Sydney time for ordinary shares holders.

What is the purpose of Bionomics (BNOX) re-domiciliation from Australia to the US?

The re-domiciliation is considered key for executing the company's strategic vision and setting up for success, as unanimously determined by the Board of Directors and an independent expert.

When and where will the Bionomics (BNOX) Scheme Meeting be held?

The Scheme Meeting will be held virtually on December 12, 2024, at 8:30 am Sydney time (December 11, 2024, 4:30 pm New York time) via the online platform at https://meetnow.global/MCKR7AV.